Key result
Higher eGFRcys/eGFRcr ratio is linked to ~63% lower odds of reduced septal e' velocity.
Why the study?
The ratio of cystatin C- to creatinine-based eGFR (eGFRcys/eGFRcr) is associated with adverse outcomes in established heart failure, but its associations with echocardiographic measures of cardiac structure and function in the general population remained incompletely characterized.
Cross-Sectional (n=5,657)
In a large population-based cohort, a higher cystatin C-to-creatinine eGFR ratio is independently associated with more favorable echocardiographic indices of left ventricular remodeling and diastolic function, supporting its role as a marker of subclinical cardio-renal interactions.
Answers are grounded in this paper and cite their sources.
Higher eGFRcys/eGFRcr ratio linked to favorable LV indices; leaves open its added value for risk stratification in the general population.
Background The ratio of cystatin C– to creatinine-based estimated glomerular filtration rate (eGFRcys/eGFRcr) has emerged as an integrative marker associated with adverse outcomes in patients with established heart failure. However, its associations with echocardiographic measures of cardiac structure and function in the general population remain incompletely characterized. Methods In an exploratory cross-sectional analysis of a population-based cohort (n=5,657; 48.1% men), associations between eGFRcys/eGFRcr-ratio and echocardiographic measures were examined. Linear regression was used for continuous outcomes and logistic regression for dichotomized echocardiographic abnormalities. Multivariable models included age, sex, systolic blood pressure, diabetes, smoking, and body mass index. Results In multivariable linear regression analyses, higher eGFRcys/eGFRcr ratio was associated with lower indexed left ventricular mass (LVMI; β −2.8 g/m², 95%CI(−5.1,−0.4), p=0.020) and lower interventricular septal thickness in diastole (IVSd; β −0.05 cm, 95%CI (−0.07,−0.03), p<0.001), as well as higher LVEF (β +1.0%, 95%CI(0.3,1.7), p=0.005) and stroke volume (β +6.1 mL, 95%CI(3.8,8.4), p<0.001). Higher eGFRcys/eGFRcr ratio was further associated with more favorable diastolic indices, including higher septal e′ velocity (β +0.85 cm/s, 95%CI(0.57,1.14), p<0.001) and lower LAVi (β −1.7 mL/m², 95%CI(−2.8,−0.6), p=0.002), as well as higher TAPSE (β +1.3 mm, 95%CI(0.8,1.8), p<0.001). In logistic regression analyses, higher eGFRcys/eGFRcr ratio was associated with lower odds of reduced septal e′ velocity (<7 cm/s; OR 0.37, 95%CI(0.22,0.63), p<0.001) and left atrial enlargement (LAVi >34 mL/m²; OR 0.65, 95%CI(0.45,0.95), p=0.026). Associations with left ventricular hypertrophy [MM1] and elevated E/e′ [MM2] were not statistically significant after multivariable adjustment. Conclusions In a large population-based cohort, higher eGFRcys/eGFRcr-ratio was independently associated with multiple favorable echocardiographic measures of cardiac structure and function, particularly indices of left ventricular remodeling and diastolic function. These findings support eGFRcys/eGFRcr as a marker of subclinical cardio–renal interactions beyond traditional measures of kidney function.
No takes yet. Share an insight, caveat, or question.
Holm et al. (2026) conducted a cross-sectional in Subclinical cardiac structure and function in the general population (n=5,657). Cystatin C-to-creatinine eGFR ratio (eGFRcys/eGFRcr) was evaluated on Reduced septal e' velocity (<7 cm/s) and other echocardiographic measures of cardiac structure and function (OR 0.37, 95% CI 0.22-0.63, p=<0.001). Higher eGFRcys/eGFRcr ratio was associated with lower LVMI and lower odds of reduced septal e' velocity.
Synapse has enriched 10 related papers. Consider them for comparative context: